Gilead Sciences stock (US3755581036): Tubulis acquisition sharpens oncology focus

Gilead Sciences has completed the acquisition of German biotech Tubulis, expanding its oncology pipeline around antibody-drug conjugates while maintaining a strong infectious disease franchise that remains closely watched by US investors.

Gilead Sciences has completed its previously announced acquisition of German clinical-stage biotech Tubulis, a move designed to strengthen its position in antibody-drug conjugates (ADCs) and broaden its oncology pipeline, according to a company press release dated May 20, 2026.Gilead Sciences as of 05/20/2026 The transaction follows a multi-year diversification push beyond HIV and hepatitis C and comes shortly after Gilead’s first-quarter 2026 results.Gilead Sciences as of 05/13/2026

As of: 05/22/2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Gilead Sciences
• Sector/industry: Biopharmaceuticals
• Headquarters/country: Foster City, United States
• Core markets: HIV, viral hepatitis, oncology and inflammatory diseases
• Key revenue drivers: HIV therapies, hepatitis treatments, cell therapy and other antivirals
• Home exchange/listing venue: Nasdaq (ticker: GILD)
• Trading currency: US dollar (USD)

Gilead Sciences: core business model

Gilead Sciences is a large biopharmaceutical company focused on discovering, developing and commercializing therapies for serious diseases, with a historic emphasis on viral infections such as HIV and hepatitis C. Its strategy has gradually expanded toward oncology and inflammatory conditions, aiming to balance mature antiviral franchises with newer growth areas that can support long-term revenue stability.

In its infectious disease core, Gilead markets widely used antiretroviral therapies for HIV treatment and prevention and maintains a portfolio addressing hepatitis B, hepatitis C and respiratory viruses. These segments have generated significant cash flows over the past decade, allowing the company to reinvest in research, in-licensing, and acquisitions such as cell therapy specialist Kite and the recent Tubulis deal, while also funding shareholder returns through dividends and buybacks when approved by the board.

Oncology has become a second strategic pillar as management aims to build a diversified cancer portfolio spanning cell therapy, small molecules and ADCs. Kite, a Gilead company, is focused on cell therapies for hematologic malignancies, while the parent organization has pursued partnerships and acquisitions in solid tumors and targeted therapies. This diversification is intended to lessen dependence on any single product class and to tap into large cancer markets relevant to US and global healthcare systems.

Main revenue and product drivers for Gilead Sciences

Gilead’s HIV franchise remains a key revenue engine, with multiple once-daily combination regimens in treatment and a growing presence in pre-exposure prophylaxis for at-risk populations. The company reported that its HIV portfolio continued to contribute a substantial share of total product sales in the first quarter of 2026, reflecting both new patient starts and ongoing treatment of existing patients, according to its quarterly update.Gilead Sciences as of 05/13/2026

Beyond HIV, hepatitis and other liver disease treatments remain important, even as some markets mature. Gilead has continued to invest in research aimed at chronic hepatitis B, nonalcoholic steatohepatitis and other liver-related conditions, seeing opportunities in underserved segments. The company also presents new data in viral hepatitis and primary biliary cholangitis at international liver congresses, underlining its intention to sustain relevance in hepatology.Gilead Sciences as of 05/13/2026

Oncology and cell therapy have grown in importance, particularly through Kite’s chimeric antigen receptor T-cell (CAR T) therapies approved for certain hematologic cancers. These products, while more specialized and often used later in treatment lines, can command significant pricing and serve as a growth area relative to some mature antivirals. The addition of Tubulis’ ADC platform is intended to complement cell therapy by providing a technology that links antibodies to potent payloads, potentially expanding Gilead’s reach into solid tumors and earlier-line treatment opportunities.

Tubulis acquisition: expanding in antibody-drug conjugates

On May 20, 2026, Gilead announced the completion of its acquisition of Tubulis, a private Germany-based clinical-stage biotechnology firm specializing in ADC technologies. According to the company, Tubulis brings a platform for designing ADCs with the aim of improving stability, payload delivery and tolerability, which could help address limitations seen with some earlier-generation ADCs.Gilead Sciences as of 05/20/2026

The acquisition is positioned as a strategic move to deepen Gilead’s oncology capabilities beyond its existing antibody-drug conjugate collaborations and cell therapy portfolio. Management highlighted that Tubulis’ proprietary conjugation technologies and pipeline candidates could be integrated with Gilead’s oncology development infrastructure, potentially accelerating the company’s presence in solid tumors and other high-need cancer indications. Financial details were not restated in the closing announcement, but the deal aligns with the broader industry trend of large biopharmaceutical companies investing in ADCs.

For US investors, the Tubulis acquisition represents another step in Gilead’s broader transition toward a balanced portfolio combining virology and oncology. While ADCs remain a competitive arena with multiple large players, Gilead’s decision to acquire a platform company rather than rely solely on external partnerships suggests an intention to own more of the underlying intellectual property in targeted oncology. Future clinical data readouts and regulatory milestones from Tubulis-derived candidates may serve as catalysts impacting market perceptions of Gilead’s oncology growth prospects.

Partnership with WHO targets visceral leishmaniasis

In parallel with its oncology initiatives, Gilead has reinforced its public health commitments. On May 21, 2026, the World Health Organization announced the renewal and expansion of its partnership with Gilead to accelerate elimination of visceral leishmaniasis, a fatal parasitic disease affecting vulnerable populations in several regions.World Health Organization as of 05/21/2026

Under the renewed collaboration, Gilead is providing financial support and medical donations to back WHO programs focused on diagnosis, treatment and prevention in endemic countries. The initiative illustrates how the company’s portfolio extends beyond commercially dominant indications to include neglected tropical diseases, which can have significant social and economic impacts despite representing smaller direct revenue opportunities. For shareholders, such collaborations may inform perceptions of the company’s environmental, social and governance profile as public health responsibilities gain prominence in investment frameworks.

The partnership also reflects Gilead’s longstanding involvement in global access and disease elimination programs, including initiatives for HIV and viral hepatitis. While the direct financial impact of efforts like visceral leishmaniasis elimination is less visible than that of flagship products, the broader reputational and policy implications can matter for a company with large international operations and frequent interactions with regulators and global health organizations.

Recent clinical and medical conference activity

Gilead and its Kite subsidiary plan to present new data at major oncology congresses in 2026, including meetings of the American Society of Clinical Oncology and the European Hematology Association. According to a joint announcement, the presentations will cover progress across ADCs and cell therapy, underscoring the company’s dual-track strategy in cancer treatment.Kite Pharma as of 05/15/2026

The data set is expected to include updates on approved and investigational cell therapies, as well as early-stage ADC programs. Such scientific visibility at key conferences is important for companies competing for physician attention, guideline inclusion and future collaboration partners. For investors, positive or negative trial readouts disclosed around or during these events can influence assessments of the probability of success for PIPELINE programs, particularly in indications with high unmet need or crowded competitive landscapes.

In liver disease, Gilead has scheduled presentations at the 2026 congress of the European Association for the Study of the Liver, with a focus on primary biliary cholangitis and viral hepatitis. The company has emphasized its goal of advancing standards of care in chronic liver diseases through novel mechanisms and combination approaches.Gilead Sciences as of 05/13/2026 These scientific activities reinforce the importance of research and development productivity for sustaining revenue in the face of generic competition and evolving treatment algorithms.

Why Gilead Sciences matters for US investors

Gilead is a long-established component of the US biopharmaceutical landscape, trading on Nasdaq under the ticker GILD and included in several major healthcare and broad market indices. Its scale, diversified portfolio and cash flows from HIV and other antivirals make it a notable name for US investors who follow large-cap healthcare. The stock can be influenced by changes in prescription trends, pricing policy, patent cliffs and competitive launches in both infectious disease and oncology.

US investors also monitor Gilead’s capital allocation choices, including research spending, acquisitions like Tubulis, and shareholder return mechanisms such as dividends and buybacks when authorized. These decisions shape the risk and growth profile of the company over multi-year horizons. In addition, regulatory developments in the United States related to drug pricing, reimbursement and intellectual property protection can directly affect the company’s US revenues and may have knock-on effects on its global strategy.

Because Gilead combines mature franchises with pipeline-dependent growth, the stock often reacts to clinical trial outcomes, regulatory decisions and competitive data disclosures. For US-based portfolios, the company provides exposure to themes such as HIV prevention, curative approaches to viral infections, cutting-edge cell therapies and ADC technology, as underscored by the Tubulis transaction and the anticipated oncology and liver disease data at 2026 medical meetings.

Conclusion

The completion of the Tubulis acquisition, renewed WHO partnership on visceral leishmaniasis and upcoming oncology and liver disease data underline how Gilead Sciences is seeking to balance its established antiviral base with expanding oncology ambitions and global health commitments. For US investors, the company remains a prominent Nasdaq-listed biopharmaceutical name whose value is shaped by the performance of core HIV and liver franchises, the success of newer platforms such as cell therapy and ADCs, and the evolving policy environment around drug pricing and access. As clinical and regulatory milestones unfold, market participants will continue to evaluate whether Gilead’s strategic pivot toward oncology and diversified therapeutic areas can sustain long-term growth alongside its mature virology portfolio.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.